Payment overview · 2025
General Payments
$795.51
38 reported records · 19 companies
Healthcare provider profile · identity verified
Michael D. Marsh, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · TOLUCA LAKE, CA · NPI 1619992047
Verified facts
What the public records show
CMS Open Payments records show Michael D. Marsh, M.D. received $795.51 in general payments during 2025 across 38 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 13.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Mounjaro, Paxlovid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $106.81 | 13.4% | 6 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $87.31 | 11.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $75.74 | 9.5% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $69.09 | 8.7% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $60.06 | 7.5% | 2 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $53.18 | 6.7% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $47.29 | 5.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $37.90 | 4.8% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.73 | 4.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.05 | 3.9% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $27.79 | 3.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.27 | 3.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $26.25 | 3.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.73 | 2.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.02 | 2.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.96 | 2.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.57 | 2.0% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.42 | 1.9% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $14.34 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $795.51 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $82.08 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $75.74 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $69.09 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $56.69 | 3 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $53.18 | 2 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $50.12 | 3 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $47.29 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $36.73 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $27.79 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $27.27 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $26.25 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $26.25 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.96 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $15.42 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $8.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 11 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 52 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
48 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
52 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
87 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
124 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 762 | 185 |
| Levothyroxine Sodium | Levothyroxine Sodium | 480 | 109 |
| Amlodipine Besylate | Amlodipine Besylate | 409 | 112 |
| Gabapentin | Gabapentin | 341 | 81 |
| Lisinopril | Lisinopril | 304 | 72 |
| Metformin Hcl | Metformin Hcl | 272 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 261 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 244 | 70 |
| Meloxicam | Meloxicam | 237 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 229 | 54 |
| Ozempic | Semaglutide | 200 | 33 |
| Alprazolam | Alprazolam | 194 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 176 | 51 |
| Montelukast Sodium | Montelukast Sodium | 161 | 45 |
| Losartan Potassium | Losartan Potassium | 132 | 33 |
| Eliquis | Apixaban | 124 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 123 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 121 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 119 | 31 |
| Donepezil Hcl | Donepezil Hcl | 102 | 28 |
| Trazodone Hcl | Trazodone Hcl | 102 | 27 |
| Azelastine Hcl | Azelastine Hcl | 95 | 35 |
| Ezetimibe | Ezetimibe | 94 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 93 | 27 |
| Naproxen | Naproxen | 92 | 28 |
| Sertraline Hcl | Sertraline Hcl | 89 | 15 |
| Jardiance | Empagliflozin | 87 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 87 | 22 |
| Atenolol | Atenolol | 85 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 38 |
| Baclofen | Baclofen | 81 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 77 | 24 |
| Tramadol Hcl | Tramadol Hcl | 77 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 73 | 15 |
| Dutasteride | Dutasteride | 71 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 70 | 57 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 17 |
| Simvastatin | Simvastatin | 70 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 66 | 18 |
| Ondansetron Odt | Ondansetron | 65 | 28 |
| Azithromycin | Azithromycin | 64 | 58 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 19 |
| Allopurinol | Allopurinol | 62 | 20 |
| Memantine Hcl | Memantine Hcl | 61 | 13 |
| Methylprednisolone | Methylprednisolone | 60 | 48 |
| Aripiprazole | Aripiprazole | 59 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 15 |
| Diazepam | Diazepam | 57 | 11 |
| Clonidine Hcl | Clonidine Hcl | 56 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 54 | 13 |
| Potassium Chloride | Potassium Chloride | 54 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 52 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | 12 |
| Famotidine | Famotidine | 49 | 11 |
| Finasteride | Finasteride | 49 | 18 |
| Januvia | Sitagliptin Phosphate | 49 | 11 |
| Mounjaro | Tirzepatide | 49 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 48 | 11 |
| Synthroid | Levothyroxine Sodium | 48 | 16 |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Omeprazole | Omeprazole | 47 | 12 |
| Valacyclovir | Valacyclovir Hcl | 47 | 14 |
| Lorazepam | Lorazepam | 45 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 45 | 14 |
| Benazepril Hcl | Benazepril Hcl | 42 | suppressed |
| Carvedilol | Carvedilol | 42 | 11 |
| Cephalexin | Cephalexin | 41 | 31 |
| Furosemide | Furosemide | 40 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | suppressed |
| Clonazepam | Clonazepam | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | suppressed |
| Kerendia | Finerenone | 37 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 36 | suppressed |
| Ibuprofen | Ibuprofen | 36 | 12 |
| Valsartan | Valsartan | 36 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | suppressed |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 30 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 27 |
| Glimepiride | Glimepiride | 29 | suppressed |
| Hydrocortisone | Hydrocortisone | 29 | 16 |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Progesterone | Progesterone, Micronized | 17 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Norethindrone Acetate | Norethindrone Acetate | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $795.51 · 38 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | CAPLYTA, CONTRAVE, Cologuard Collection Kit, FANAPT, GEMTESA, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, PAXLOVID, QULIPTA, RELISTOR, REXULTI, SUBLOCADE, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VRAYLAR, XIFAXAN, Xhance, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error